Current approaches to controlling type 2 diabetes
- Authors: Ametov A.S.1, Karpova E.V.1, Ivanova E.V.1, Ametov AS1, Karpova EV1, Ivanova EV1
-
Affiliations:
- ГОУ ДПО РМАПО Росздрава
- Issue: Vol 81, No 10 (2009)
- Pages: 20-27
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30520
- ID: 30520
Cite item
Full Text
Abstract
Keywords
About the authors
Aleksandr Sergeevich Ametov
ГОУ ДПО РМАПО Росздрава
Email: endocrine@mtu.net.ru
кафедра эндокринологии и диабетологии с курсом эндокринной хирургиид. м. н., проф., зав. кафедрой; ГОУ ДПО РМАПО Росздрава
Ekaterina Vladimirovna Karpova
ГОУ ДПО РМАПО Росздрава
Email: karpova-doc@mail.ru
кафедра эндокринологии и диабетологии с курсом эндокринной хирургииврач-эндокринолог, аспирант; ГОУ ДПО РМАПО Росздрава
Ekaterina Valer'evna Ivanova
ГОУ ДПО РМАПО Росздравакафедра эндокринологии и диабетологии с курсом эндокринной хирургииврач-эндокринолог, аспирант; ГОУ ДПО РМАПО Росздрава
A S Ametov
E V Karpova
E V Ivanova
References
- International Diabetes Federation. Diabetes and cardiovascular disease: Time to act. Brussels: International Diabetes Federation; 2001.
- King H., Aubert R. E., Herman W. H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabet. Care 1998; 21 (9): 1414-1431.
- Niskanen L., Turpeinen A., Penttila I., Uusitupa M. I. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabet. Care 1998; 21 (11): 1861-1869.
- Manson J. E., Colditz G. A., Stampfer M. J. et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch. Intern. Med. 1991; 151: 1141-1147.
- Neaton J. D., Wentworth D. N., Cutler J. et al. Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. Ann. Epidemiol. 1993; 3: 493-499.
- Stratton J. M., Adler A. I., Neil A. W. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective, observational study. Br. Med. J. 2000; 321: 405-412.
- Дедов И. И., Шестакова М. В. Сахарный диабет. М.: Универсум Паблишинг; 2003: 231-242; 244-256; 263-267, 282-289.
- Дедов И. И., Шестакова М. В. Диабетическая нефропатия. М.: Универсум Паблишинг; 2000: 239.
- Lustman P. J., Clouse R. E. Depression in diabetic patients: the relationship between mood and glycemic control. J. Diabet. Complicat. 2005; 19 (2): 113-122.
- Avignon A., Radauceanu A., Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabet. Care 1997; 20: 1822-1826.
- Bonora E., Calcaterra F., Lombardi S. et al. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabet. Care. 2001; 24: 2023-2029.
- Rohlfing C. L., Wiedmeyer H. S., Little R. et al. Defining the relationship between plasma glucose and HbA1c. Diabet. Care. 2002; 25: 275-278.
- American Diabetes Association: Standards of medical care in diabetes. Diabet. Care 2006; 29 (suppl. 1): S4-S42.
- Sacks D. B., Bruns D. E., Goldstein D. E. et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (Position Statement). Diabet. Care 2002; 25: 750-786.
- Gorus Fm., Mathieu C., Gerlo E. How should HbAlc measurements be reported? Diabetologia 2006; 49: 7-10.
- Selvin E., Marinopoulos S., Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004; 141: 421-431.
- Aldasouqi S. A., Gossain V. V. Hemoglobin A1c: Past, present and future. Ann. Saudi Med. 2008; 28 (6): 411-419.
- Cooppan R. Type 2 Diabetes: The Pathophysiologic Basis of Treatment Design, http://cme.medscape.com/viewprogram/ 17327_learning
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-853.
- Parris E. S., Lawrence D. B., Mohn L. A., Long L. B. Diabet. Care 2005; 28 (3): 595-599.
- Karalliedde J., Gnudi L. ACCORD and ADVANCE: a tale of two studies on the Merits control in type 2 diabetic patients. Nephrol. Dial. Transplant. 2008; 23 (6): 1796-1798.
- Soo Yeon S., Nesto R. W. Implications of intensive glycemic control on cardiovascular disease: early reports from the ACCORD and ADVANCE Trials. Rev.Cardiovasc. Med. 2008, 9 (l): 1-4.
- Radermecker R. P., Philips J. C., Jandrain B. et al. Blood glucose control and cardiovascular disease in patiens with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials. Rev. Med. Liege 2008; 63 (7-8): 511-518.
- Hauner H. HbAlc of 6.5%. A rigid goal in diabetes therapy? (interview by Dr. Dirk Einecke). MMW Fortschr. Med. 2008; 150 (26-27): 16.
- Füchtenbusch M., Hummel M. Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study. MMW Fortschr. Med. 2008; 150 (17): 42-44.
- Patel A. ADVANCE Collaborative Group, MacMahon S., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840.
- Monami M. Are sulfonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabet. Metab. Res. Rev. 2007; 23: 479-484.
- Selvin E., Marinopoulos S., Berkenblit G. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004; 141: 421-431.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9141): 837-853.
- Dluhy R. G., McMahon G. T. Intensive glycemic control in the ACCORD and ADVANCE trials. N. Engl. Med. 2008; 358 (24): 2630-2633.
- Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009; 360: 129-139.
- Stettler C., Allemann S., Jüni P. et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am. Heart. J. 2006; 52: 27-38.
- Nathan D. M., Cleary P. A., Backlund J. Y. et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005; 353: 2643-2653.
- Gaede P., Lund-Andersen H., Parving H.-H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Eng. Med. 2008; 358: 580-591.
- Skyler J. S., Bergenstal R., Bonow R. O. et al. Expert consensus document. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. J. Am. Coll. Cardiol. 2009; 53: 298-304.
- Reichard P., Bengt-Nilsson B.-Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 1993; 329: 304-309.
- The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-986.
- Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabet. Res. Clin. Pract. 1995; 28: 103-117.
- Buse J. B., Ginsberg H. N., Bakris G. L. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126.
- The ADVANCE Collaborative Group. N. Engl. J. Med. 2008; 358; 2560-2572.
- ADVANCE Management Committee. Study Rational and Design of ADVANCE: Action in diabetes and vascular disease-preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120.